MECP2 and Alzheimer disease: (1) Trofinetide’s FDA approval for Rett syndrome (MECP2 mutations causing transcriptional dysregulation and synaptic dysfunction) does not predict efficacy for Alzheimer’s disease pathogenesis involving fundamentally distinct mechanisms (amyloid cascade, tauopathy, neuroinflammation, synaptic loss).